The role and treatment of inflammation in dry eye disease

International Ophthalmology

Volumn 34, Issue 6, 2014, Pages 1291-1301

  Yagci, Ayse ^a   Gurdal, Canan ^b  

^a EGE UNIVERSITY   (Turkey)

^b BOZOK UNIVERSITY   (Turkey)

Author keywords

Cyclosporine A; Dry eye syndromes; Etiology; Inflammation; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; ESSENTIAL FATTY ACID; IMMUNOMODULATING AGENT; TETRACYCLINE; ANGIOGENESIS INHIBITOR; BIOLOGICAL FACTOR; IMMUNOSUPPRESSIVE AGENT;

CORTICOSTEROID THERAPY; DRY EYE; EYE INFLAMMATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY (TOPIC); NONHUMAN; OSMOLARITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURFACE PROPERTY; CHEMISTRY; COMPLICATION; DRY EYE SYNDROMES; INFLAMMATION; LACRIMAL FLUID; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL FACTORS; DRY EYE SYNDROMES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; OSMOLAR CONCENTRATION; RISK FACTORS; TEARS;

EID: 84920999983     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-014-9969-x     Document Type: Review

References (101)

1. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5(2):75–92
2. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143(3):409–415
3. Stevenson W, Chauhan SK, Dana R (2012) Dry eye disease: an immune mediated ocular surface disorder. Arch Ophthalmol 130(1):90–100
4. Barabino S, Chen Y, Chauhan S, Dana R (2012) Ocular surface immunity: homeostastic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 31:271–285
5. Alves M, Fonseca EC, Alves MF et al (2013) Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf 11(3):181–192
6. Pflugfelder SC, Corrales RM, de Paiva CS (2013) T helper cytokines in dry eye disease. Exp Eye Res 117:118–125
7. Stern ME, SchaumburgCS Dana R, Calonge M, Niederkorn JY, Pflugfelder SC (2010) Authoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol 3:425–442
8. Baudouin C, Aragona P, Messmer E et al (2013) Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of OCEAN group meeting. Ocul Surf 11(4):246–258
9. Stern ME, Schaumburg CS, Pflugfelder SC (2013) Dry eye as a mucosal autoimmune disease. Int Rev Ophthalmol 32:19–41
10. Stern ME, Gao J, Siemasko KF et al (2004) The role of lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 78:409–416
11. Cursiefe C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 92:50–57
12. Ellenberg D, Azar DT, Hallak JA et al (2010) Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 29(3):208–248. doi:10.1016/j.preteyeres.2010.01.002
13. Pflugfelder SC, De Paiva CS, Villarreal AL et al (2008) Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 27(1):64–69
14. El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R (2009) Characterization of effector T cells in dry eye disease. Investig Ophthalmol Vis Sci 50(8):3802–3807
15. Shen L, Barabino S, Taylor AW, Dana MR (2007) Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol 125:908–915
16. Hamrah P, Liu Y, Zhang Q, Dana M (2003) Alteration in corneal stromal dentritic cell phenotype and distribution in inflammation. Arch ophtalmol 121:1132–1140
17. Li DQ, Chen Z, Song XJ et al (2004) Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Investig Ophthalmol Vis Sci 45(12):4302–4311
18. Lam H, Bleiden L, de Paiva CS et al (2009) Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 147:198–205
19. Enríquez-de-Salamanca A, Castellanos E, Stern ME et al (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16:862–873
20. Chen Y, Chauhan SK, Saban DR et al (2011) Interferon-γ secreting NK cells promote induction of dry eye disease. J Leukoc Biol 89:965–972
21. Yeh S, Song XJ, Farley W et al (2003) Apoptosis of ocular surface cells in experimentally induced dry eye. Investig Ophthalmol Vis Sci 44(1):124–129
22. Perry HD (2008) Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 14(3):79–87
23. Gao J, Morgan G, Tieu D et al (2004) ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res 78:823–835
24. Chauhan SK, El Annan J, Ecoiffier T et al (2009) Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 182:1247–1252
25. Dohlman TH, Chauhan SK, Kodati S et al (2013) The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. Investig Ophthalmol Vis Sci 54:4081–4091
26. de Paiva CS, Villarreal AL, Corrales RM et al (2007) Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-{gamma}. Investig Ophthalmol Vis Sci 48:2553–2560
27. Corrales RM, Stern ME, De Paiva CS et al (2006) Desiccating stress stimulates expression of matrix metalloproteinases by corneal epithelium. Investig Ophthalmol Vis Sci 47(8):3293–3302
28. Chauhan SK, Jin Y, Goyal S et al (2011) A novel pro-lymphangiogenic function for Th17/IL17. Blood 118:4630–4634
29. de Paiva CS, Chotikavanich S, Pangelinan SB et al (2009) IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2(3):243–253
30. Dastjerdi MH, Dana R (2009) Corneal nerve alterations in dry eye–associated ocular surface disease. Int Ophthalmol Clin 49(1):11–20
31. Villani E, Magnani F, Viola F et al (2013) In vivo confocal evaluation of the ocular surface morpho-functional unit in dry eye. Optom Vis Sci 90:576–586
32. Labbe´ A, Alalwani H, Van Went C et al (2012) The relationship between sub-basal nerve morphology and corneal sensation in ocular surface disease. Investig Ophthalmol Vis Sci 53:4926–4931
33. Eldridge DC, Sullivan BD, Berg MD, Durrie DS, Lemp MA (2010) Longitudinal variability of tear film osmolarity in normal and dry eye patients. Investig Ophthalmol Vis Sci 51(5):3379–3381
34. Goto T, Zheng X, Okamoto S, Ohashi Y (2004) Tear film stability analysis system: introducing a new application for videokerathography. Cornea 23(8 suppl):65–70
35. Sambursky R, Davitt WF 3rd, Latkany R et al (2013) Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immünoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 131(1):24–28
36. Wei Y, Gadaria-Rathod N, Epstein SP et al (2013) Tear cytokine profile as a non-invasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Investig Ophthalmol Vis Sci 7:8327–8336
37. Epstein SP, Gadaria-Rathod N, Wei Y et al (2013) HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease. Exp Eye Res 111:95–104
38. Villani E, Galimberti D, Del Papa N et al (2013) Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study. Innate Immün 19(4):42
39. Kanellopoulos AJ, Asimellis G (2014) In vivo 3-dimensional corneal epithelial thickness mapping as an indicator of dry eye: preliminary clinical assessment. Am J Ophthalmol 157:63–68
40. Villani E, Mantelli F, Nucci P (2013) In-vivo confocal microscopy of the ocular surface: ocular allergy and dry eye. Curr Opi Allergy Clin Immunol 13:569–576
41. Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R (2007) The cornea in Sjogren’s syndrome: an in vivo confocal study. Investig Ophthalmol Vis Sci 48:2017–2022
42. Mantopoulos D, Cruzat A, Hamrah P (2010) In vivo imaging of corneal inflammation: new tools for clinical practice and research. Semin Ophthalmol 25(5–6):178–185
43. Villani E, Baudouin C, Efron N et al (2014) In vivo confocal microscopy of the ocular surface: from bench to bedside. Cuurent Eye Res 39(3):213–231
44. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf 5(2):163–178
45. Behrens A, Doyle JJ, Stern L, Dysfunctional tear syndrome study group et al (2006) Dysfunctional tear syndrome a Delphi approach to treatment recommendations. Cornea 25:900–907
46. Asbell PA (2006) Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin 22:2149–2157
47. Iskeleli G, Kizilkaya M, Arslan OS et al (2002) The effect of artificial tears on corneal surface regularity in patients with Sjögren syndrome. Ophthalmologica 216:118–122
48. Huang FC, Tseng SH, Shih MH et al (2002) Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 109:1934–1940
49. Kaercher T, Buchholz P, Kimmich F (2009) Treatment of patients with keratoconjunctivitis sicca with Optive™: results of a multicenter, open-label observational study in Germany. Clin Ophthalmol 3:33–39
50. Guillon M, Maissa C, Ho S (2010) Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage. Contact Lens Anterior Eye 33(2):93–99
51. Gomes JA, Amankwah R, Powell-Richards A et al (2004) Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol 88:821–825
52. Vehige JG, Simmons PA, Anger C et al (2003) Cytoprotective properties of carboxymethyl cellulose (CMC) when used prior to wearing contact lenses treated with cationic disinfecting agents. Eye Contact Lens 29:177–180
53. Lee JH, Ahn HS, Kim EK et al (2011) Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 30:175–179
54. Chen W, Zhang X, Li J et al (2013) Efficacy of osmoprotectants on prevention and treatment of murine dry eye. Investig Ophthalmol Vis Sci 54(9):6287–6297
55. Tong L, Petznick A, Lee SY, Tan J (2012) Choice of artificial tear formulation for patients with dry eye: Where do we start? Cornea 31(Supp 1):32–36
56. Corrales RM, Luo L, Chang EY et al (2008) Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 27:574–579
57. Baudouin C, Cochener B, Pisella PJ et al (2012) Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol 22(5):751–761
58. Pflugfelder SC (2004) Anti-inflammatory therapy for dry eye. Am J Ophthalmol 137:337–342
59. de la Maza Sainz, Serra SM, Simon Castellvi C, Kabbani O (2000) Nonpreserved topical steroids and punctal occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol 75:751–756
60. Dogru M, Tsubota K (2011) Pharmocotherapy of dry eye. Expert opin Pharmacother 12(3):325–334
61. Pflugfelder SC, Maskin SL, Anderson B et al (2004) A randomized, double masked, placebo-controlled, multicenter comparison of loteprednoletabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138:444–457
62. Gündüz K, Özdemir Ö (1994) Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol 72:438–442
63. Ben Ezra D, Matamoros N, Cohen E (1988) Treatment of severe vernal keratoconjunctivitis with cyclosporine A eye drops. Transplant Proc 20(2 Suppl 2):644–649
64. Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 107:967–974
65. Sall K, Stevenson OD, Mundorf TK et al (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology 107:631–639
66. Donnenfeld E, Pflugfelder SC (2009) Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 54(3):321–338
67. Utine CA, Stern M, Akpek EK (2010) Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immünol Inflamm 18(5):352–361
68. Baudouin C, Brignole F, Pisella PJ et al (2002) Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol 506:761–769
69. Kunert KS, Tisdale AS, Stern ME et al (2011) Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 118:1489–1496
70. Turner K, Pflugfelder SC, Ji Z et al (2000) Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporin ophthalmic emulsion. Cornea 19:492–496
71. Gürdal C, Genç I, Saraç O et al (2010) Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res 35(9):771–777
72. Kunert KS, Tisdale AS, Gipson IK (2002) Goblet cell numbers and epithelial proliferation in the conjunctiva of dry eye syndrome treated with cyclosporin. Arch Ophthalmol 120:330–337
73. Agarwal R, Jain AM, Saxena N et al (2013) Effect of topical cyclosporine (0.05 %) on conjunctival impression cytology in dry eye. J Evol Med Dental Sci 2(24):4277–4281
74. Sahli E, Hosxal BM, Zilelioglu G et al (2010) The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea 29:1412–1416
75. Brignole F, Pisella PJ, De Saint Jean M et al (2001) Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Investig Ophthalmol Vis Sci 42:90–95
76. Wang J, Cui L, Shen M et al (2012) Ultra-high resolution optical coherence tomography for monitoring tear meniscus volume in dry eye after topical cyclosporine treatment. Clin Ophthalmol 6:933–938. doi:10.2147/OPTH.S32384
77. Prabhasawat P, Tesavibul N, Mahawong W (2012) A randomized double-masked study of 0.05 % cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 31:1386–1393
78. Perry HD, Carnevale SD, Donnenfeld ED et al (2006) Efficacy of commercially available topical cyclosporine A 0.05 % in the treatment of meibomian gland dysfunction. Cornea 25:171–175
79. Small DS, Acheampong A, Reis B et al (2002) Blood concentrations of cyclosporine a during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 18:411–418
80. Perry HD, Donnenfeld ED (2004) Topical 0.05 % cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5(10):2099–2107
81. Perry HD, Solomon R, Donnenfeld ED et al (2008) Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 126(8):1046–1050
82. Dastjerdi MH, Hamrah P, Dana R (2009) High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28(10):1091–1096
83. ®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05 % for dry eye: a retrospective review. Clin Ophthalmol 6:1971–1976
84. Rao SN (2010) Topical cyclosporine 0.05 % for the prevention of dry eye disease progression. J Ocul Pharmacol Ther 26(2):157–164
85. Cross WD, Lay LF Jr, Walt JG et al (2002) Clinical and economic implications of topical cyclosporin A for the treatment of dry eye. Manag Care Interface 15(9):44–49
86. Brown MM, Brown GC, Brown HC et al (2009) Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 127(2):146–152
87. Shine WE, McCulley JP, Pandya AG (2003) Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 76:417–420
88. Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265
89. Krakauer T, Buckley M (2003) Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 47:3630–3633
90. Solomon A, Rosenblatt M, Li DQ et al (2000) Doxycycline inhibition of interleukin-1 in the corneal epithelium. Investig Ophthalmol Vis Sci 41:2544–2557
91. Maatta M, Kari O, Tervahartiala T et al (2006) Tear fluid levels of MMP-8 are elevated in ocular rosacea: treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 244:957–962
92. Geerling G, Tauber J, Baudouin C et al (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investig Ophthalmol Vis Sci 52(4):2050–2064
93. James MJ, Gibson RA, Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71(1 Suppl):343–348
94. Barabino S, Rolando M, Camicione P et al (2003) Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 22:97–101
95. Kojima T, Ishida R, Dogru M et al (2005) The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139:242–246
96. Versura P, Profazio V, Buzzi M et al (2013) Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 32(4):412–418
97. Tanaka H, Fukuda K, Ishida W et al (2013) Rebamipide increases barrier function and attenuates TNFα-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br J Ophthalmol 97(7):912–916
98. Kimura K, Morita Y, Orita T et al (2013) Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide. Investig Ophthalmol Vis Sci 54(4):2572–2760
99. Ohguchi T, Kojima T, Ibrahim OM et al (2013) The effects of 2 % rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Investig Ophthalmol Vis Sci 54(12):7793–7802
100. Ji YW, Byun YJ, Choi W et al (2013) Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye. Investig Ophthalmol Vis Sci 54(12):7557–7566
101. Huet E, Vallée B, Delbé J et al (2011) EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Am J Pathol 179(5):1278–1286